Dronedarone should be avoided in older adults with which conditions?

Study for the AGS Beers Criteria Test. Prepare with flashcards and multiple choice questions, each with hints and explanations. Get ready for your exam with comprehensive resources!

Multiple Choice

Dronedarone should be avoided in older adults with which conditions?

Explanation:
Dronedarone is avoided in older adults when there is permanent atrial fibrillation or severe or recently decompensated heart failure because safety data show a higher risk of harm in these situations without a clear, meaningful benefit. In permanent AF, the rhythm-control advantage of dronedarone is unlikely to be realized, so exposing patients to potential adverse effects isn’t justified. In those with severe or recently decompensated heart failure, dronedarone can worsen heart function and has been linked to increased mortality and hospitalizations. Because older adults often have limited cardiac reserve and multiple comorbidities, the Beers Criteria flags this combination as potentially inappropriate. In other scenarios, like hypertension or pulmonary disease without decompensation, the concern is less pronounced, though individual risk and drug interactions should still be considered.

Dronedarone is avoided in older adults when there is permanent atrial fibrillation or severe or recently decompensated heart failure because safety data show a higher risk of harm in these situations without a clear, meaningful benefit. In permanent AF, the rhythm-control advantage of dronedarone is unlikely to be realized, so exposing patients to potential adverse effects isn’t justified. In those with severe or recently decompensated heart failure, dronedarone can worsen heart function and has been linked to increased mortality and hospitalizations. Because older adults often have limited cardiac reserve and multiple comorbidities, the Beers Criteria flags this combination as potentially inappropriate. In other scenarios, like hypertension or pulmonary disease without decompensation, the concern is less pronounced, though individual risk and drug interactions should still be considered.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy